ImmunityBio, Inc. IBRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$854.6M-109% | -$351.47M+15.0% | -$348.69M+40.7% | -$367.17M+38.6% | -$409.18M+32.0% | ||
| $16.08M-4.5% | $15.53M-11.6% | $15.8M-12.1% | $16.3M-10.0% | $16.83M-8.5% | ||
| $35.44M-0.7% | $36.81M+6.9% | $37.1M-2.8% | $35.71M-20.9% | $35.7M-23.3% | ||
| $26.24M— | $40.21M— | —— | —— | —— | ||
| $11.14M+31.9% | $6.33M-23.5% | $4.75M+142% | $4.83M+167% | $8.44M— | ||
| —— | —— | —— | —— | -$1.04M+63.2% | ||
| $19.25M— | $3.18M— | -$855K— | -$98K— | —— | ||
| —— | —— | —— | $146K+116% | $1.32M+183% | ||
| $343K— | $570K— | —— | —— | —— | ||
| -$169K+75.0% | $0+100% | -$690K+55.2% | -$684K+56.1% | -$675K+57.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$294.39M+20.5% | -$304.94M+22.1% | -$319.7M+24.1% | -$349.56M+14.7% | -$370.16M+4.9% | ||
| $4.5M-33.3% | $3.85M-44.2% | $5.05M-60.3% | $7.11M-54.5% | $6.75M-71.2% | ||
| $380.37M+314% | $241.37M+72.1% | $201.84M+50.3% | $21.25M-85.3% | $91.96M+57.0% | ||
| —— | —— | —— | —— | $107.92M+367% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $41K-4.7% | $28K-56.3% | $16K-81.0% | $26K-67.9% | $43K-45.6% | ||
| $8.06M+188% | $2.27M-58.6% | $2.48M-60.2% | $2.63M-64.5% | $2.8M-59.7% | ||
| $625.15M+131% | $400.24M+42.1% | $452.28M+20.5% | $294.34M-50.7% | $270.42M-45.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $75.84M-9.7% | $71.32M-22.7% | $73.6M-36.4% | $78.89M-20.8% | $84M-1.9% | ||
| $4.22M+302% | $2.75M+84.4% | $1.07M-32.8% | $667K-34.7% | $1.05M+67.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$1.04M+63.2% | ||
| —— | —— | —— | —— | $972K— | ||
| $19.25M— | $3.18M— | -$855K— | -$98K— | —— | ||
| $36.28M-16.1% | $41.23M+8.5% | $42.88M+53.3% | $44.08M+152% | $43.27M— | ||
| $250K+122% | $250K+122% | -$1.15M-715% | -$1.15M+70.0% | -$1.15M+82.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | $14.02M— | $10.51M— | $7.01M— | $3.5M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $560.25K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $107.92M+367% | ||
| $41K-4.7% | $28K-56.3% | $16K-81.0% | $26K-67.9% | $43K-45.6% | ||
| —— | —— | —— | —— | $0-100% | ||
| —— | —— | —— | —— | $0— | ||
| $53.54M-9.5% | $0-100% | $0-100% | $15.62M-72.9% | $59.17M+319% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $245.88M+1,254% | -$49.09M-146% | -$28.08M-141% | -$44.5M-152% | -$21.31M-128% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $75M+3.1% | $0-100% | $24.24M-90.9% | $48.48M-79.9% | $72.72M— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $7.62M— | $5.9M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $429K-46.7% | $293K-63.6% | $1.03M+1,397% | $923K— | $805K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$298.89M+20.7% | -$308.78M+22.4% | -$324.76M+25.2% | -$356.66M+16.2% | -$376.91M+8.7% | ||
| -$298.89M+20.7% | -$308.78M+22.4% | -$324.76M+25.2% | -$356.66M+16.2% | -$376.91M+8.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
